EP1968645A4 - Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses - Google Patents
Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and usesInfo
- Publication number
- EP1968645A4 EP1968645A4 EP06846650A EP06846650A EP1968645A4 EP 1968645 A4 EP1968645 A4 EP 1968645A4 EP 06846650 A EP06846650 A EP 06846650A EP 06846650 A EP06846650 A EP 06846650A EP 1968645 A4 EP1968645 A4 EP 1968645A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- mimetibodies
- compositions
- methods
- related disorders
- treating obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75282605P | 2005-12-22 | 2005-12-22 | |
PCT/US2006/062223 WO2007076319A2 (en) | 2005-12-22 | 2006-12-18 | Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1968645A2 EP1968645A2 (en) | 2008-09-17 |
EP1968645A4 true EP1968645A4 (en) | 2009-11-04 |
Family
ID=38218787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06846650A Withdrawn EP1968645A4 (en) | 2005-12-22 | 2006-12-18 | Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1968645A4 (en) |
JP (1) | JP2009526750A (en) |
CA (1) | CA2634784A1 (en) |
WO (1) | WO2007076319A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200843794A (en) | 2006-12-21 | 2008-11-16 | Centocor Inc | Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles |
WO2009059278A1 (en) * | 2007-11-02 | 2009-05-07 | Centocor, Inc. | Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses |
WO2009099961A2 (en) | 2008-01-31 | 2009-08-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Engineered antibody constant domain molecules |
TWI829687B (en) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid |
CN113677702A (en) | 2019-04-01 | 2021-11-19 | 诺和诺德股份有限公司 | Antibodies against liraglutide and uses thereof |
JP2023528921A (en) | 2020-06-03 | 2023-07-06 | ケブンハウンス、ウニバーシテート | GLP1R agonist/NMDAR antagonist conjugate |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1750754A4 (en) * | 2004-03-31 | 2010-09-22 | Centocor Ortho Biotech Inc | Human glp-1 mimetibodies, compositions, methods and uses |
-
2006
- 2006-12-18 CA CA002634784A patent/CA2634784A1/en not_active Abandoned
- 2006-12-18 EP EP06846650A patent/EP1968645A4/en not_active Withdrawn
- 2006-12-18 JP JP2008547703A patent/JP2009526750A/en active Pending
- 2006-12-18 WO PCT/US2006/062223 patent/WO2007076319A2/en active Application Filing
Non-Patent Citations (3)
Title |
---|
ADELHORST K ET AL: "STRUCTURE-ACTIVITY STUDIES OF GLUCAGON-LIKE PEPTIDE-1", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM, US, vol. 269, no. 9, 4 March 1994 (1994-03-04), pages 6275 - 6278, XP002045291, ISSN: 0021-9258 * |
NASLUND E ET AL: "Glucagon-like peptide-1 in the pathogenesis of obesity", DRUG NEWS AND PERSPECTIVES 1998 ES, vol. 11, no. 2, 1998, pages 92 - 97, XP001539560, ISSN: 0214-0934 * |
PICHA KRISTEN M ET AL: "Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis", DIABETES, vol. 57, no. 7, July 2008 (2008-07-01), pages 1926 - 1934, XP002547063, ISSN: 0012-1797 * |
Also Published As
Publication number | Publication date |
---|---|
WO2007076319A3 (en) | 2008-10-30 |
JP2009526750A (en) | 2009-07-23 |
CA2634784A1 (en) | 2007-07-05 |
EP1968645A2 (en) | 2008-09-17 |
WO2007076319A2 (en) | 2007-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200709266B (en) | Human GLP-1 mimetibodies, compositions, methods and uses | |
ZA200901132B (en) | Human GLP-1 mimetibodies, compositions, methods and uses | |
IL182837A0 (en) | Methods, assays and compositions for treating retinol-related diseases | |
EP1959929A4 (en) | Compositions and methods for treating dermatological conditions | |
IL177717A0 (en) | Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders | |
IL186963A0 (en) | Methods and compositions for treating pain | |
HUE039108T2 (en) | Compositions and methods for treating ophthalmic disorders | |
IL190913B (en) | Compositions for the treatment sweat related disorders | |
EP1890712A4 (en) | Compositions and methods for treating pain | |
PL1863899T3 (en) | Skin treatment compositions | |
IL179766A0 (en) | Compositions and methods using same for treating neurodegenerative disorders | |
HK1214158A1 (en) | Formulations and methods for treating amyloidosis | |
IL185861A0 (en) | Method and composition for treating mucosal disorders | |
ZA200804500B (en) | Methods and compositions for the treatment of gastro-intestinal disorders | |
EP2120994A4 (en) | Methods and compositions for treating hypoglycemic disorders | |
EP1968645A4 (en) | Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses | |
EP1898921A4 (en) | Compositions and methods for treating sleep disorders | |
EP1942909A4 (en) | Methods for treating respiratory disorders | |
ZA200708408B (en) | Method and composition for treating mucosal disorders | |
GB0715870D0 (en) | Composition and methods for reducing body fat content, treating obesity and related disorders | |
IL186307A0 (en) | Human glp-1 mimetibodies, compositions, methods and uses | |
GB0424214D0 (en) | Method,composition and device for treating starch related diseases | |
ZA200608999B (en) | Human GLP-1 mimetibodies, compositions, methods and uses | |
PL2374472T3 (en) | Compositions and methods for treating ophthalmic disorders | |
GB2433935B (en) | Compounds for treating diabetes and related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20080718 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
R17D | Deferred search report published (corrected) |
Effective date: 20081030 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 5/00 20060101ALI20081118BHEP Ipc: A61K 38/04 20060101ALI20081118BHEP Ipc: A61K 38/00 20060101AFI20081118BHEP |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1124539 Country of ref document: HK |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: CENTOCOR ORTHO BIOTECH INC. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20091005 |
|
17Q | First examination report despatched |
Effective date: 20100204 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100615 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1124539 Country of ref document: HK |